Savara Inc (NASDAQ:SVRA) Shares Purchased by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC grew its holdings in shares of Savara Inc (NASDAQ:SVRA) by 33.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 988,468 shares of the company’s stock after purchasing an additional 245,834 shares during the period. ADAR1 Capital Management LLC owned 0.58% of Savara worth $3,035,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of SVRA. The Manufacturers Life Insurance Company lifted its holdings in Savara by 9.0% in the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock worth $191,000 after acquiring an additional 3,706 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Savara by 14.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after purchasing an additional 4,732 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Savara by 5.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock valued at $533,000 after purchasing an additional 6,141 shares during the period. SG Americas Securities LLC grew its stake in Savara by 14.0% during the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after buying an additional 6,330 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Savara by 6.8% in the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock worth $434,000 after buying an additional 9,041 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SVRA. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Savara in a research note on Friday, March 28th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Finally, Wells Fargo & Company assumed coverage on Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Stock Performance

SVRA opened at $2.85 on Monday. The business has a 50 day moving average price of $2.73 and a two-hundred day moving average price of $3.20. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company has a market capitalization of $492.00 million, a price-to-earnings ratio of -6.63 and a beta of 0.52. Savara Inc has a 1-year low of $2.26 and a 1-year high of $5.34.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million during the quarter. Research analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.